3519-30-0

Basic information

• Product Name: L-ALPHAHYDROXYISOVALERIC ACID T-BUTYL ESTER
• Synonyms: L-ALPHAHYDROXYISOVALERIC ACID T-BUTYL ESTER;Butanoic acid, 2-hydroxy-3-methyl-, 1,1-dimethylethyl ester, (2S)-;(S)-Alphahydroxyisovaleric acid t-butyl ester;(S)-tert-butyl 2-hydroxy-3-methylbutanoate;tert-Butyl (2S)-2-hydroxy-3-methylbutanoate;tert-butyl (S)-2-hydroxy-3-methylbutanoate
• CAS NO: 3519-30-0
• Molecular Formula: C₉H₁₈O₃
• Molecular Weight: 174.24
• Product Categories: chiral;Miscellaneous
• Mol File: 3519-30-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 189.5°C at 760 mmHg
• Flash Point: 63°C
• Appearance: /
• Density: 0.974g/cm³
• Vapor Pressure: 0.155mmHg at 25°C
• Refractive Index: 1.437
• CAS DataBase Reference: L-ALPHAHYDROXYISOVALERIC ACID T-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: L-ALPHAHYDROXYISOVALERIC ACID T-BUTYL ESTER(3519-30-0)
• EPA Substance Registry System: L-ALPHAHYDROXYISOVALERIC ACID T-BUTYL ESTER(3519-30-0)

Safety Data

• Hazardous Substances Data: 3519-30-0(Hazardous Substances Data)

Usage

General Description

L-Alpha Hydroxyisovaleric Acid T-Butyl Ester, also known as 2,2-Dimethyl-4-morpholinecarboxylic acid, is a chemical compound belonging to the family of Alpha Hydroxy Acids (AHAs). AHAs are organic acids with one hydroxyl group attached to the alpha position of the acid. They are commonly used in skin care products not only for their exfoliating properties, but also for their ability to promote collagen synthesis, improve the appearance of wrinkles and fine lines, and enhance the overall health and look of the skin. L-Alpha Hydroxyisovaleric Acid T-Butyl Ester, due to its highly lipophilic nature, may aid in the penetration of active ingredients into the skin. More specific information about its properties, usage, or safety would depend on its application and concentration in a product.

InChI:InChI=1/C9H18O3/c1-6(2)7(10)8(11)12-9(3,4)5/h6-7,10H,1-5H3/t7-/m0/s1

Upstream product

• 72-18-4 L-valine 
• 110-78-1 Propyl isocyanate 
• 2528-17-8 α-hydroxy-isovaleric acid t-butyl ester 
• 18667-97-5 (S)-2-acetoxy-3-methylbutanoic acid 
• 17407-55-5 (S)-2-Hydroxy-3-methylbutanoic acid 
• 380886-48-6 tert-butyl (S)-2-acetoxy-3-methylbutanoate 
• 82301-82-4 O-Peoc-L-2-hydroxy-3-methylbytansaeure-t-butylester 

Downstream Products

• 11042-59-4 neoantimycin 
• 1218922-72-5 (R)-tert-butyl 2-(N-isopropoxy-4-methoxyphenylsulfonamido)-3-methylbutanoate 
• 1178858-85-9 tert-butyl (R)-2-(4-bromo-N-isopropoxyphenylsulfonamido)-3-methylbutanoate 
• 18671-23-3 N-Benzyloxycarbonyl-N-methyl-L-Val-L-α-hydroxy-isovaleryl-N-methyl-L-Val-L-α-hydroxy-isovaleriansaeure-tert.-butylester 
• 18668-12-7 2-(N-benzyloxycarbonyl-N-methylamino)-3-methylbutyric acid 1-carboxy-2-methylpropyl ester 
• 18668-13-8 N-Benzyloxycarbonyl-N-methyl-D-Val-L-α-hydroxy-isovaleriansaeure 
• 3092-24-8 Benzyloxycarbonyl-D-valyl-D-leucyl-L-α-hydroxy-isovaleriansaeure 
• 3275-32-9 Benzyloxycarbonyl-D-valyl-D-leucyl-L-α-hydroxy-isovaleryl-L-valyl-N-methyl-L-leucyl-L-α-hydroxy-isovaleriansaeure-tert-butylester 

Relevant articles and documents

First total synthesis of neoantimycin

The first total synthesis of neoantimycin (1), an unusual ring-extended antibiotic of the antimycin class, has been achieved, using intramolecular transesterification for construction of the 15-membered tetralactone core.

Zinc-catalyzed enantiospecific sp3-sp3 cross-coupling of α-hydroxy ester triflates with grignard reagents

(Chemical Equation Presented) Zinc chloride does the trick and efficiently catalyzes the enantiospecific cross-coupling of α-hydroxy ester triflates with Grignard reagents under mild conditions. Enantiopure α-hydroxy esters are directly available from the chiral pool or by diazotization of α-amino acids. Substantial variations in both reacting partners are tolerated making this methodology an attractive alternative to enolate alkylation featuring a reversal of polarity.

N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP

Structural manipulation of the pharmacophoric model of type A selective MMP inhibitors (MMPi), obtained by the insertion of some alkyl substituents R 2 possessing an appropriate geometry, steric bulkiness and lipophilicity, is able to improve p